Immunotherapy is changing the paradigm of multiple myeloma (MM) management and daratumumab is the first-in-class human monoclonal antibody targeting CD38 approved for the treatment of this malignancy. Daratumumab exerts anti-myeloma activity by different
Massimo Offidani +6 more
doaj +2 more sources
Safety and Efficacy of Subcutaneous Daratumumab in Systemic AL Amyloidosis
Michael Sang Hughes, Suzanne Lentzsch Department of Hematology-Oncology, Columbia University Irving Medical Center, New York, NY, USACorrespondence: Suzanne Lentzsch, Department of Hematology-Oncology, Columbia University Irving Medical Center, MH-6GN ...
Hughes MS, Lentzsch S
doaj +1 more source
Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth [PDF]
Background The monoclonal antibody daratumumab, approved for treating myeloma, targets CD38, a protein on myeloma and also on CD34+ hematopoietic progenitor cells.
Xun Ma +13 more
doaj +2 more sources
Aggressive Hepatic AL Amyloidosis Encountering Therapeutic Frailty: Rapid Organ Reversal With Tailored Daratumumab-Based Therapy and Low-Dose Corticosteroids in a Patient With Steroid-Induced Psychosis. [PDF]
ABSTRACT Hepatic AL amyloidosis can cause severe cholestasis independent of marrow tumor burden. In patients with absolute contraindications to high‐dose steroids—such as steroid‐induced psychosis—tailored daratumumab regimens with low‐dose corticosteroids can drive rapid, life‐saving organ reversal.
Ceccarelli R +8 more
europepmc +2 more sources
Daratumumab-induced transient myopic shift [PDF]
Purpose: To describe an unprecedented case of transient myopic shift induced by a chemotherapeutic agent, daratumumab. Observations: A 43-year-old emmetropic female with multiple myeloma experienced sudden onset of myopic shift during her first ...
Maria A. Mavrommatis +4 more
doaj +2 more sources
: Daratumumab, a human CD38 imunoglobulin G 1κ monoclonal antibody, has demonstrated clinical activity and a manageable safety profile in monotherapy and combination therapy clinical trials in relapsed and/or refractory multiple myeloma.
Tineke Casneuf +13 more
doaj +2 more sources
Real-World Retrospective Analysis of Daratumumab for Relapsed or Refractory Multiple Myeloma in Regional Australia. [PDF]
This retrospective case series evaluated all patients treated with daratumumab between 2018 and 2023 across two regional hospitals in Australia. Fifty‐two patients were included with a median age of 74. Median progression‐free survival (PFS) was 13 months and overall survival (OS) was 27 months, with an overall response rate was 35%.
Reardon B, Kerridge I, Armytage T.
europepmc +2 more sources
Bispecific antibodies targeting B-cell maturation antigen in multiple myeloma: Current clinical applications, challenges and future directions. [PDF]
Abstract Anti‐B cell maturation antigen (BCMA) therapies, including antibody‐drug conjugates, chimeric antigen receptor T cells, and bispecific antibodies (bsAbs), have recently revolutionized the treatment landscape of multiple myeloma. This review outlines the biologic rationale for targeting BCMA and sheds light on the mechanism of action of bsAbs ...
Manzato E +5 more
europepmc +2 more sources
Real-world outcomes of daratumumab, bortezomib, thalidomide and dexamethasone (Dara-VTd) induction and lenalidomide maintenance in transplant-eligible multiple myeloma. [PDF]
British Journal of Haematology, Volume 209, Issue 5, Page 2321-2325, November 2026.
Crusoé EQ +20 more
europepmc +2 more sources
Cytarabine-based mobilisation yields higher CD34+ cell counts than cyclophosphamide regardless of prior daratumumab exposure in multiple myeloma [PDF]
IntroductionAnti-CD38-based quadruplets such as daratumumab-bortezomib-lenalidomide-dexamethasone (D-VRd) or daratumumab-bortezomib-thalidomide-dexamethasone (D-VTd), where lenalidomide is not reimbursed, are the internationally recommended first-line ...
Wojciech Szlasa +8 more
doaj +2 more sources

